Ceritinib - Novartis
Alternative Names: Jikadia; LDK-378; NVP-LDK 378; NVP-LDK378-NX; ZykadiaLatest Information Update: 11 Dec 2023
At a glance
- Originator Novartis
- Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; University of Texas Southwestern Medical Center
- Class Antineoplastics; Diamines; Piperidines; Pyrimidines; Small molecules; Sulfones
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Gastrointestinal cancer; Haematological malignancies; Solid tumours; Thyroid cancer
- No development reported Malignant melanoma
Most Recent Events
- 10 Nov 2023 Novartis completes a phase III ASCEND-5 trial for Non-small cell lung cancer (late-stage disease, Metastatic-disease, second-line or greater therapy) in USA, Belgium, Canada, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, South Korea, Lebanon, Netherlands, Portugal, Russia, Switzerland, Turkey, United Kingdom, Singapore, Spain (PO) (NCT01828112)
- 28 Aug 2022 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in Jordan (PO, Capsule)
- 28 Aug 2022 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Late-stage disease, Second-line therapy or greater) in Philippines (PO, Capsule)